Aurobindo Pharma Lannett acquisition set to close by end of June after FTC nod
The Aurobindo Pharma Lannett deal is almost done. An acquisition is when one company buys another. India’s Aurobindo Pharma will finish buying a US medicine maker called Lannett by the end of June 2026. The price is about $250 million. A US watchdog called the FTC (the Federal Trade Commission, America’s competition watchdog) has now said yes to the deal. This is a big step in Aurobindo’s plan to grow in the United States.
Here is the deal in simple words. Aurobindo’s US team is buying Lannett. Lannett makes generic drugs. Generic drugs are cheaper copies of brand-name medicines. The price is about $250 million. And the watchdog has now cleared it.
What exactly is being bought
The buyer is Aurobindo Pharma USA, Inc. This is a US arm fully owned by Aurobindo Pharma Limited. Aurobindo is one of India’s biggest drug companies. The company being bought is Lannett Company LLC. Lannett is based in the US state of Pennsylvania.
The price is about $250 million. The deal is “cash-free, debt-free.” This simply means Lannett’s spare cash and its loans are taken out of the price. So the $250 million is the value of the real business. It is not the cash in its bank or the money it owes.
Lannett makes hard-to-copy generic medicines. It focuses on “non-opioid controlled substances.” Controlled substances are drugs the government watches closely, because people can misuse them. “Non-opioid” means they are not addictive painkillers like opioids. These drugs are hard to make. So fewer rivals can copy them. That makes Lannett’s products more valuable.
Why the FTC had to say yes first
In the US, when one company buys another, a watchdog often checks the deal first. The FTC (the US competition watchdog) tries to stop deals that hurt buyers by killing competition. If a deal would let one firm raise prices unfairly, the FTC can block it. It can also ask the firms to change the deal.
Here, the FTC said yes. The companies did not report any forced sale of products. (Sometimes a watchdog tells a buyer to sell off some products so competition stays healthy.) With the FTC’s yes in hand, Aurobindo said the deal should close before the end of June 2026.
The real prize: a US factory
The biggest prize may not be money. It may be a factory. Lannett runs a factory in Seymour, Indiana. The company says this site can make about 4 billion doses a year. That is a large US factory that is ready to use.
Why does a US factory matter so much? Most Indian drug firms make medicines in India. Then they ship them to America. But the US now wants more medicines made on its own land. A local factory helps Aurobindo do that. The company linked the deal to “US policy priorities aimed at improving supply chain resilience.” A supply chain is the path goods take from maker to buyer. Resilience means key goods can still be made even during a crisis.
Key facts (as reported)
| Detail | What was reported |
|---|---|
| Buyer | Aurobindo Pharma USA, Inc. (arm of Aurobindo Pharma) |
| Target | Lannett Company LLC, Pennsylvania, USA |
| Deal value | About $250 million (cash-free, debt-free) |
| Regulator approval | US FTC cleared the deal |
| Expected close | Before end of June 2026 |
| Lannett’s focus | Complex generics; non-opioid controlled substances |
| US factory | Seymour, Indiana; about 4 billion doses a year |
| Earnings effect | Said to be immediately accretive to EPS |
What the bosses said
Swami S. Iyer is the CEO of Aurobindo Pharma USA. (A CEO is the top boss of a company.) He called the deal “a significant strategic and financial opportunity.” He said it would speed up sales growth. He also said it would make the company’s US factories stronger.
Tim Crew is Lannett’s CEO. He spoke of his company’s “proud history of helping patients access affordable medicines.” He said joining Aurobindo would help more people get those medicines. Aurobindo’s money and sales network would make this easier.
What it means for Aurobindo’s numbers
Aurobindo said the deal will be “immediately accretive” to its EPS. EPS means earnings per share. It is how much profit the company makes for each share. (A share is one small piece of a company that people can own.) “Immediately accretive” means the deal should lift that profit per share right away, not years later.
The company also expects “SG&A synergies” and cost savings. SG&A means selling, general and administrative costs. These are the everyday running costs of a business, like pay, offices and ads. “Synergies” means the two firms together can cut some of these costs by sharing them. In short, the two joined firms may cost less to run than two separate ones.
Investors are happy. (Investors are people who put money into a company hoping it grows.) Aurobindo’s shares had gone up about 26% in 2026 so far. The Nifty Pharma index went up only about 8% in the same time. (An index is a basket that tracks the share prices of many big drug companies at once.)
The bigger US generics push
The US is the world’s biggest market for medicines. Generic drugs make up most of the prescriptions filled there. (A prescription is a doctor’s note that lets you buy a medicine.) Indian firms like Aurobindo already supply a big share of these cheap copies. So winning more space in the US is a top goal.
This move fits a bigger trend. Many Indian drug firms are buying or building US sites. This gets them closer to customers. It also helps them avoid shipping and trade risks. The Aurobindo Pharma Lannett deal is one of the clearest recent examples of this plan in action.
FAQ
How much is Aurobindo paying for Lannett?
About $250 million, on a cash-free, debt-free basis. That means Lannett’s spare cash and loans are not counted in the price.
When will the deal close?
Aurobindo expects to close the deal before the end of June 2026, now that the FTC has said yes.
What does Lannett actually make?
Lannett makes hard-to-copy generic medicines. It focuses on non-opioid controlled substances. These drugs are hard to copy, which makes them more valuable.
Why is a US factory important here?
Lannett’s factory in Seymour, Indiana can make about 4 billion doses a year. A US factory helps Aurobindo serve American demand. It also lowers trade and supply risks.
Why it matters (especially for India / founders)
For India, this deal shows how its drug industry is moving up. Indian firms are no longer just sellers who ship abroad. They are now buying US factories and hard-to-copy product lines. This brings higher profits. It also gives them a stronger spot in the world’s richest medicine market.
For founders and business students, there are clear lessons. First, owning a base where your customer is can beat shipping from far away. This is even more true when trade rules get tense. Second, watchdog approval is a real step in any cross-border deal, so plan for it. Third, look at how Aurobindo framed the win: a ready factory, hard-to-copy products, shared cost savings, and a quick boost to profit. Good deals usually stack several of these benefits at once.
This story sits alongside other India business moves we covered in this batch, such as the bigbasket new CEO appointment, where leadership and strategy shifts are reshaping major Indian firms.
The takeaway
The Aurobindo Pharma Lannett deal gives the Indian drugmaker a US factory, a hard-to-copy generics line, and a clearer path to grow in America. The FTC has said yes, and the deal will close by end of June. The next thing to watch is how fast the two businesses join up. We will also watch how much it lifts Aurobindo’s US sales.
Source: Financial Express
